Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance t...Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance to prexasertib in triple negative breast cancer(TNBC).Methods:Using a panel of pre-clinical TNBC cell lines,we measured the sensitivity to prexasertib.We examined the effect activation of EGFR had on prexasertib sensitivity.We measured the synergy of dual blockade of EGFR with erlotinib and CHK1 with prexasertib in TNBC cell lines and xenografts.Results:EGFR overexpression and activation increased resistance to CHK1 inhibition by prexasertib.EGFR promoted the phosphorylation of BCL2-associated agonist of cell death(BAD),inactivating its pro-apoptotic functions.Inhibition of EGFR reversed BAD phosphorylation,increasing sensitivity to prexasertib.Conclusion:The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses.We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers.EGFR expression status should be considered in clinical trials examining prexasertib’s use as a monotherapy or combination therapy.展开更多
Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance t...Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance to prexasertib in triple negative breast cancer(TNBC).Methods:Using a panel of pre-clinical TNBC cell lines,we measured the sensitivity to prexasertib.We examined the effect activation of EGFR had on prexasertib sensitivity.We measured the synergy of dual blockade of EGFR with erlotinib and CHK1 with prexasertib in TNBC cell lines and xenografts.Results:EGFR overexpression and activation increased resistance to CHK1 inhibition by prexasertib.EGFR promoted the phosphorylation of BCL2-associated agonist of cell death(BAD),inactivating its pro-apoptotic functions.Inhibition of EGFR reversed BAD phosphorylation,increasing sensitivity to prexasertib.Conclusion:The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses.We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers.EGFR expression status should be considered in clinical trials examining prexasertib’s use as a monotherapy or combination therapy.展开更多
基金This work was supported by an Innovation Award from the Breast Cancer Research Foundation of Alabama to MS and NRG(www.brcaf.org)GW is supported by a pre-doctoral fellowship through the University of South Alabama College of Medicine.
文摘Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance to prexasertib in triple negative breast cancer(TNBC).Methods:Using a panel of pre-clinical TNBC cell lines,we measured the sensitivity to prexasertib.We examined the effect activation of EGFR had on prexasertib sensitivity.We measured the synergy of dual blockade of EGFR with erlotinib and CHK1 with prexasertib in TNBC cell lines and xenografts.Results:EGFR overexpression and activation increased resistance to CHK1 inhibition by prexasertib.EGFR promoted the phosphorylation of BCL2-associated agonist of cell death(BAD),inactivating its pro-apoptotic functions.Inhibition of EGFR reversed BAD phosphorylation,increasing sensitivity to prexasertib.Conclusion:The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses.We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers.EGFR expression status should be considered in clinical trials examining prexasertib’s use as a monotherapy or combination therapy.
基金This work was supported by an Innovation Award from the Breast Cancer Research Foundation of Alabama to MS and NRG(www.brcaf.org)GW is supported by a pre-doctoral fellowship through the University of South Alabama College of Medicine.
文摘Aim:Innate resistance to the CHK1 inhibitor prexasertib has been described,but resistance mechanisms are not understood.We aimed to determine the role epidermal growth factor receptor(EGFR)plays in innate resistance to prexasertib in triple negative breast cancer(TNBC).Methods:Using a panel of pre-clinical TNBC cell lines,we measured the sensitivity to prexasertib.We examined the effect activation of EGFR had on prexasertib sensitivity.We measured the synergy of dual blockade of EGFR with erlotinib and CHK1 with prexasertib in TNBC cell lines and xenografts.Results:EGFR overexpression and activation increased resistance to CHK1 inhibition by prexasertib.EGFR promoted the phosphorylation of BCL2-associated agonist of cell death(BAD),inactivating its pro-apoptotic functions.Inhibition of EGFR reversed BAD phosphorylation,increasing sensitivity to prexasertib.Conclusion:The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses.We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers.EGFR expression status should be considered in clinical trials examining prexasertib’s use as a monotherapy or combination therapy.
